Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 40Recurrence 9Neoplasms, Plasma Cell 7Waldenstrom Macroglobulinemia 3Neoplasms 3Lymphoma, B-Cell 3Burkitt Lymphoma 3Sarcoma, Kaposi 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Acquired Immunodeficiency Syndrome 2Unspecified Adult Solid Tumor, Protocol Specific 1Renal Insufficiency 1Plasmablastic Lymphoma 1Optic Nerve Glioma 1Neurofibromatosis 1 1Myeloproliferative Disorders 1Multi-centric Castleman's Disease 1Leukemia, Myeloid, Acute 1Intraocular Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Hematologic Diseases 1Epstein-Barr Virus Infections 1Disease Progression 1Disease 1Central Nervous System Neoplasms 1Amyloidosis 1

Interventions

Temozolomide 30Radiotherapy 23Filgrastim 12Carmustine 12Irinotecan 11Carboplatin 11Chemotherapy, Adjuvant 9O(6)-benzylguanine 8Etoposide 7Surgical Procedures, Operative 6Magnetic Resonance Spectroscopy 6Vincristine 5Peripheral Blood Stem Cell Transplantation 5Granulocyte Colony-Stimulating Factor 5Cyclophosphamide 5sargramostim 4motexafin gadolinium 4Topotecan 4Thiotepa 4Paclitaxel 4Melphalan 4Gene Expression Profiling 4Gemcitabine 4Drug Therapy 4Busulfan 4temsirolimus 3etoposide phosphate 3Specimen Handling 3Mass Spectrometry 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Central Nervous System Neoplasms × pomalidomide × Clear all
NCT02415153 2022-04-25

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

National Cancer Institute (NCI)

Phase 1 Completed
29 enrolled
CNS

Neurofibromatosis 1, Central Nervous System Neoplasms, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡